Unknown

Dataset Information

0

Hepatocellular carcinoma tumor thrombus entering the inferior vena cava treated with percutaneous RF ablation: a case report.


ABSTRACT:

Purpose

Hepatocellular carcinoma (HCC) is the most common form of liver cancer. In advanced cancer stages (metastatic disease and/or vascular invasion), the generally accepted standard of care is systemic therapy using sorafenib as first-line treatment and, recently, regorafenib and nivolumab as second-line treatment, but the quality of life and the prognosis of patients remain very poor. Our paper reports a case of US-guided radiofrequency ablation (RFA) of both intraparenchymal HCC and inferior vena cava tumor thrombus.

Methods

We treated a patient with HCC associated with tumor thrombus extending into vena cava after failure of sorafenib therapy using US-guided radiofrequency ablation (RFA).

Results

A good radiological and clinical response was observed in association with excellent tolerability. The patient has been followed up for 15 months from the ablation, is alive, and is in a good clinical condition without evidence of tumor recurrence.

Conclusion

This is the first case in which this minimally invasive percutaneous procedure has been successfully used to treat an HCC thrombus entering the vena cava.

SUBMITTER: Gatti P 

PROVIDER: S-EPMC6704268 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Hepatocellular carcinoma tumor thrombus entering the inferior vena cava treated with percutaneous RF ablation: a case report.

Gatti Pietro P   Giorgio Antonio A   Ciracì Emanuela E   Roberto Italia I   Anglani Alessandro A   Sergio Spano S   Rizzello Fernando F   Giorgio Valentina V   Semeraro Stefano S  

Journal of ultrasound 20190312 3


<h4>Purpose</h4>Hepatocellular carcinoma (HCC) is the most common form of liver cancer. In advanced cancer stages (metastatic disease and/or vascular invasion), the generally accepted standard of care is systemic therapy using sorafenib as first-line treatment and, recently, regorafenib and nivolumab as second-line treatment, but the quality of life and the prognosis of patients remain very poor. Our paper reports a case of US-guided radiofrequency ablation (RFA) of both intraparenchymal HCC and  ...[more]

Similar Datasets

| S-EPMC10236862 | biostudies-literature
| S-EPMC7563051 | biostudies-literature
| S-EPMC8651468 | biostudies-literature
| S-EPMC7093783 | biostudies-literature
| S-EPMC10990751 | biostudies-literature
| S-EPMC4736520 | biostudies-other
| S-EPMC8647260 | biostudies-literature
| S-EPMC10413311 | biostudies-literature
| S-EPMC8717523 | biostudies-literature